

ASLAN Pharma partners with Belle.ai for Atopic Dermatitis clinical trials

30 August 2022 | News

To use bellestudy image capture software in the trials



US-based BelleTorus Corporation and Singapore's ASLAN Pharmaceuticals have announced that ASLAN has licensed belleStudy digital image capture software in support of ASLAN's clinical trials for atopic dermatitis (AD) across several global sites.

ASLAN will make the image capture software component of belleStudy available to all investigators of TREK-AD, its ongoing global phase 2b trial of eblasakimab, expected to generate topline data in the first half of 2023.

"This technology allows us to enhance our quality control procedures without having to adjust our protocols in this ongoing study," said Dr Alex Kaoukhov, Chief Medical Officer, ASLAN Pharmaceuticals.

The belleStudy image capture software on a smartphone camera guides clinical investigators to clearly and accurately capture photos of AD before being uploaded to a cloud server. Belle.ai's precise artificial intelligence (AI) algorithms provide qualitative assessment (identification) and quantitative scoring (severity) of atopic dermatitis and over 1,000 skin conditions, delivering cutting edge digital solutions which could be leveraged by ASLAN in future AD studies.